Mavacamten对非梗阻性肥厚型心肌病心脏生物标志物的影响:ODYSSEY-HCM试验探索性分析
ODYSSEY-HCM试验虽未在主要终点(功能容量和患者报告健康状况)显示改善,但本探索性分析纳入580例症状性非梗阻性肥厚型心肌病患者,发现Mavacamten治疗48周较安慰剂显著降低NT-proBNP和hs-cTnI,且降幅早期出现并维持至48周。
要点
- Mavacamten治疗48周使NT-proBNP几何均值比0.42(降58%),hs-cTnI几何均值比0.49(降51%),均P<0.001。
- 安慰剂组两种生物标志物均无显著变化。
- 生物标志物改善是否转化为长期重构逆转及临床获益尚待明确。
核心结论
- 在症状性非梗阻性肥厚型心肌病患者中,Mavacamten治疗48周与安慰剂相比带来显著的生物标志物改善。
研究设计与样本
- ODYSSEY-HCM试验(NCT05582395)的探索性分析,580例症状性nHCM患者随机接受安慰剂或Mavacamten(起始5 mg/d,根据左室射血分数在1–15 mg间滴定)。
- 基线及第48周测量NT-proBNP和hs-cTnI,并结合临床、运动及超声心动图参数进行分析。
主要发现
- 基线中位NT-proBNP为917.5 ng/L(IQR 463–1,725 ng/L),hs-cTnI为29.1 ng/L(IQR 14.4–91.7 ng/L)。
- 多变量分析中,女性、体重指数、NYHA功能分级、最大左室壁厚度、左房容积指数和E/e'与较高基线NT-proBNP相关。
- 仅较年轻年龄和左室质量指数与较高基线hs-cTnI水平相关。
- 第48周时,Mavacamten组NT-proBNP降低58%(几何均值比0.42;95%CI 0.37–0.47;P<0.001),hs-cTnI降低51%(几何均值比0.49;95%CI 0.45–0.53;P<0.001)。
- 安慰剂组两种生物标志物均无显著变化,Mavacamten组的降低早期出现并维持至第48周。
临床怎么用
- 对于症状性nHCM患者,Mavacamten可显著降低NT-proBNP和hs-cTnI,提示心肌壁应力与损伤减轻。
- 生物标志物改善能否转化为长期适应性重构及患者报告健康状况、运动能力和结局的改善尚需进一步研究。
局限性
- 原文未报告该探索性分析的具体局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: No therapy is approved for patients with symptomatic nonobstructive hypertrophic cardiomyopathy (nHCM). The ODYSSEY-HCM (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395) trial, the largest to date in patients with hypertrophic cardiomyopathy (HCM), evaluating the efficacy of mavacamten in symptomatic adults with nHCM, did not demonstrate improvements in its primary endpoints (functional capacity and patient-reported health status). OBJECTIVES: The current exploratory analysis from the ODYSSEY-HCM trial reports the associations between: 1) baseline biomarkers (N-terminal pro-B-type natriuretic peptide [NT-proBNP] and high-sensitivity cardiac troponin I [cTnI]) with clinical, exercise, and echocardiographic characteristics; and 2) comparing changes in these biomarkers from baseline to week 48 between mavacamten and placebo groups. METHODS: Symptomatic nHCM patients were randomized to placebo or mavacamten (starting at 5 mg/d, with titration ranging from 1 to 15 mg, based on left ventricular [LV] ejection fraction). Along with clinical and echocardiographic parameters, NT-proBNP and hs-cTnI were measured for changes from baseline to week 48. RESULTS: Among 580 randomized patients (mean age 56 ± 15 years, 266 [45.9%] women), baseline biomarkers were elevated with median NT-proBNP 917.5 ng/L (IQR: 463-1,725 ng/L) and hs-cTnI of 29.1 ng/L (IQR: 14.4-91.7 ng/L). On multivariable analysis, female sex, body mass index, NYHA functional class, maximal LV wall thickness, left atrial volume index, and E/e' were associated with higher baseline NT-proBNP. Only younger age and LV mass index were associated with higher baseline hs-cTnI level. At week 48, the mavacamten group had a 58% reduction in NT-proBNP (geometric mean ratio: 0.42; 95% CI: 0.37-0.47; P < 0.001) and a 51% reduction in hs-cTnI (geometric mean ratio: 0.49; 95% CI: 0.45-0.53; P < 0.001). No significant change in either biomarker was seen in the placebo group. These reductions occurred early and were maintained through week 48. CONCLUSIONS: Treatment with mavacamten for 48 weeks in nHCM patients was associated with marked biomarker improvements compared with placebo. Whether these changes translate into longer-term adaptive remodeling and improvements in patient-reported health status, exercise capacity, and outcomes remain to be ascertained. (A Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy [ODYSSEY-HCM]; NCT05582395).
引用
- Desai MY, Olivotto I, Abraham T, et al. Effects of Mavacamten on Cardiac Biomarkers in Nonobstructive Hypertrophic Cardiomyopathy: Insights From the ODYSSEY-HCM Trial. J Am Coll Cardiol. 2025. PMID: 40864018. doi:10.1016/j.jacc.2025.08.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。